Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 2/20 | 0.37 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.37 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.36 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.36 |
| ▸ | FAAH | O00519 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26878452 | 1.00 | MTNR1A (0.37) | MTNR1AMTNR1BEPHX1EPHX2FKBP1A | |
| SCHEMBL19220265 | 1.00 | MTNR1A (0.37) | MTNR1AMTNR1BEPHX1EPHX2FKBP1A | |
| SCHEMBL19223414 | 0.98 | KDM4E (0.37) | MTNR1AMTNR1BEPHX1EPHX2FKBP1A | |
| SCHEMBL19220272 | 0.98 | KDM4E (0.37) | MTNR1AMTNR1BEPHX1EPHX2FKBP1A | |
| SCHEMBL19220271 | 0.94 | KDM4E (0.39) | MTNR1AMTNR1BEPHX1EPHX2MAPT | |
| SCHEMBL19223283 | 0.94 | KDM4E (0.39) | MTNR1AMTNR1BEPHX1EPHX2MAPT | |
| SCHEMBL19223299 | 0.90 | MTNR1A (0.34) | MTNR1AMTNR1BEPHX2MAPT | |
| SCHEMBL19220289 | 0.90 | MTNR1A (0.34) | MTNR1AMTNR1BEPHX2MAPT | |
| SCHEMBL19220288 | 0.87 | NAAA (0.36) | MTNR1AMTNR1BHPGD | |
| SCHEMBL19220269 | 0.87 | NAAA (0.36) | MTNR1AMTNR1BHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230381761-A1 | CATALYSTS AND THEIR USES IN ONE-POT DIASTEREOSELECTIVE SYNTHESIS OF REMDESIVIR | ACADEMIA SINICA (TW) | 2023-11-30 | — | — | US | disclosed |
| US-20230381761-A1 | CATALYSTS AND THEIR USES IN ONE-POT DIASTEREOSELECTIVE SYNTHESIS OF REMDESIVIR | ACADEMIA SINICA (TW) | 2023-11-30 | — | — | US | disclosed |
| US-10597422-B2 | Process for making chloro-substituted nucleoside phosphoramidate compounds | MERCK SHARP & DOHME CORP. (US) | 2020-03-24 | — | — | US | disclosed |
| US-20190144485-A1 | Process for Making Chloro-substituted Nucleoside Phosphoramidate Compounds | MERCK SHARP & DOHME LLC | 2019-05-16 | — | — | US | disclosed |
| US-20170226146-A1 | PROCESS FOR MAKING CHLORO-SUBSTITUTED NUCLEOSIDE PHOSPHORAMIDATE COMPOUNDS | MERCK SHARP & DOHME LLC | 2017-08-10 | — | — | US | disclosed |
| US-20170226146-A1 | PROCESS FOR MAKING CHLORO-SUBSTITUTED NUCLEOSIDE PHOSPHORAMIDATE COMPOUNDS | MERCK SHARP & DOHME LLC | 2017-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190144485-A1 | Process for Making Chloro-substituted Nucleoside Phosphoramidate Compounds | NUDT1, PNP, SAMHD1 | MTNR1A 4100/4885MTNR1B 3626/4885EPHX1 869/4885 |
| US-20170226146-A1 | PROCESS FOR MAKING CHLORO-SUBSTITUTED NUCLEOSIDE PHOSPHORAMIDATE COMPOUNDS | NUDT1, PNP, SAMHD1 | MTNR1A 4100/4885MTNR1B 3626/4885EPHX1 869/4885 |
| US-20230381761-A1 | CATALYSTS AND THEIR USES IN ONE-POT DIASTEREOSELECTIVE SYNTHESIS OF REMDESIVIR | MTAP, PNP, ALKBH1 | MTNR1A 3622/4885MTNR1B 3721/4885EPHX1 302/4885 |
| US-10597422-B2 | Process for making chloro-substituted nucleoside phosphoramidate compounds | NUDT1, PNP, SAMHD1 | MTNR1A 4100/4885MTNR1B 3626/4885EPHX1 869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.